secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2025-01-29T23:59:59+00:00
Accession:  0000950170-25-010199
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan's zipalertinib meets primary endpoint in Phase 2b NSCLC trial; H2 2025 FDA submission planned
--------------------------------------------------------------------------------

- REZILIENT1 trial met primary endpoint of overall response rate in NSCLC with EGFR exon 20 insertion mutations after prior therapy.
- Safety profile generally consistent with previous data presentations; full results to be submitted for upcoming medical conference.
- Pending FDA discussions, companies plan to submit for U.S. regulatory approval in second half of 2025.
- Zipalertinib (CLN-081/TAS6417) is a monotherapy for patients who have received prior therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000095017025010199/0000950170-25-010199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000095017025010199/cgem-20250128.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-010199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer